Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy-Reference-Cited by-同舟云学术

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy

Published:2022-07-06 Issue:9 Volume:97 Page:1170-1177
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Bal Susan¹²^ORCID,Dhakal Binod³^ORCID,Silbermann Rebecca W.⁴,Schmidt Timothy M.⁵,Dholaria Bhagirathbhai⁶,Giri Smith¹²^ORCID,Chhabra Saurabh³^ORCID,Medvedova Eva⁴,Godby Kelly N.¹²,D'Souza Anita³^ORCID,Hall Aric C.⁵,Hardwick Pamela¹²,Omel Jim⁷,Cornell Robert F.⁶,Hari Parameswaran³,Callander Natalie S.⁵,Costa Luciano J.¹²^ORCID

Affiliation:

1. Division of Hematology/Oncology University of Alabama at Birmingham Birmingham Alabama USA

2. O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham Birmingham Alabama USA

3. Division of Hematology/Oncology, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA

4. Division of Hematology/Medical Oncology Oregon Health & Science University Portland Oregon USA

5. Department of Medicine University of Wisconsin Madison Wisconsin USA

6. Department of Medicine, Division of Hematology and Oncology Vanderbilt University Medical Center Nashville Tennessee USA

7. Independent Patient Advocate Omaha Nebraska USA

Funder

Amgen

Janssen Research and Development

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26640

Reference30 articles.

1. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

2. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

3. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

4. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

5. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy;Frontiers in Oncology;2024-03-27

2. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial;The Lancet Haematology;2023-11

3. Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation;Annals of Hematology;2023-09-08

4. Making a case for del(1p) as a high‐risk abnormality in multiple myeloma;Cancer;2023-06-06